APB-BS2 / AprilBio - LARVOL DELTA

[Exclusive] April Bio, Development of 4 Candidate Substances Suspended... Beginning to Improve Constitution [Google translation] (Sisa Journal e) - "April Bio has decided to discontinue the development of four new drug candidates that it was researching and has excluded them from its portfolio...According to the industry on the 2nd, April Bio's IR data from the second half of last year showed that in addition to the new drug pipeline disclosed in the business report at the beginning of this year, it possessed a total of four candidate substances, including 'APB-BS2' and 'APB-R8' for solid cancer treatment, 'APB-R7' for autoimmune disease, and 'APB-R6' for endocrine disease treatment. All of these are pipelines that were in basic research at the candidate substance stage....However, it has been reported that April Bio's new drug strategy has been reorganized starting this year, and that it has decided to discontinue the development of existing single antibody candidates. This applies to APB-BS2, APB-R8, APB-R7, and APB-R6."

Discontinued • Endocrine Disorders • Immunology • Solid Tumor